celiprolol has been researched along with Cutis Elastica in 11 studies
Celiprolol: A cardioselective beta-1 adrenergic antagonist that has intrinsic sympathomimetic activity. It is used in the management of ANGINA PECTORIS and HYPERTENSION.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Patients with clinical vascular Ehlers-Danlos syndrome were randomly assigned to 5 years of treatment with celiprolol or to no treatment." | 9.14 | Effect of celiprolol on prevention of cardiovascular events in vascular Ehlers-Danlos syndrome: a prospective randomised, open, blinded-endpoints trial. ( Boutouyrie, P; Bozec, E; Collignon, P; De Backer, J; De Paepe, A; Emmerich, J; Fauret, AL; Fiessinger, JN; Georgesco, G; Germain, DP; Hulot, JS; Jeunemaitre, X; Laurent, S; Ong, KT; Perdu, J; Plauchu, H, 2010) |
| "Treatment with celiprolol is tolerated in most patients with vEDS." | 5.62 | Celiprolol Treatment in Patients with Vascular Ehlers-Danlos Syndrome. ( Baderkhan, H; Björck, M; Stattin, EL; Stenborg, A; Wanhainen, A, 2021) |
| " Patients with clinical vascular Ehlers-Danlos syndrome were randomly assigned to 5 years of treatment with celiprolol or to no treatment." | 5.14 | Effect of celiprolol on prevention of cardiovascular events in vascular Ehlers-Danlos syndrome: a prospective randomised, open, blinded-endpoints trial. ( Boutouyrie, P; Bozec, E; Collignon, P; De Backer, J; De Paepe, A; Emmerich, J; Fauret, AL; Fiessinger, JN; Georgesco, G; Germain, DP; Hulot, JS; Jeunemaitre, X; Laurent, S; Ong, KT; Perdu, J; Plauchu, H, 2010) |
| "Treatment with celiprolol is tolerated in most patients with vEDS." | 1.62 | Celiprolol Treatment in Patients with Vascular Ehlers-Danlos Syndrome. ( Baderkhan, H; Björck, M; Stattin, EL; Stenborg, A; Wanhainen, A, 2021) |
| "Pregnancy is very risky in women with vascular EDS." | 1.38 | [Vascular Ehlers-Danlos syndrome and pregnancy: an obstetrical specific support]. ( Dreyfus, M; Jamard, A; Le Hello, C; Simonet, T, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (9.09) | 29.6817 |
| 2010's | 5 (45.45) | 24.3611 |
| 2020's | 5 (45.45) | 2.80 |
| Authors | Studies |
|---|---|
| Gorosabel, MC | 2 |
| Dubacher, N | 2 |
| Meienberg, J | 2 |
| Matyas, G | 2 |
| Boutouyrie, P | 4 |
| Kelly, J | 1 |
| Lyons, O | 1 |
| Baderkhan, H | 1 |
| Wanhainen, A | 1 |
| Stenborg, A | 1 |
| Stattin, EL | 1 |
| Björck, M | 1 |
| Frank, M | 1 |
| Adham, S | 1 |
| Seigle, S | 1 |
| Legrand, A | 1 |
| Mirault, T | 1 |
| Henneton, P | 1 |
| Albuisson, J | 1 |
| Denarié, N | 2 |
| Mazzella, JM | 1 |
| Mousseaux, E | 2 |
| Messas, E | 1 |
| Jeunemaitre, X | 3 |
| Münger, J | 1 |
| Crabb, J | 1 |
| Ksiazek, AA | 1 |
| Caspar, SM | 1 |
| Bakker, ENTP | 1 |
| van Bavel, E | 1 |
| Ziegler, U | 1 |
| Carrel, T | 1 |
| Steinmann, B | 1 |
| Zeisberger, S | 1 |
| Brooke, BS | 2 |
| Ong, KT | 1 |
| Perdu, J | 2 |
| De Backer, J | 1 |
| Bozec, E | 1 |
| Collignon, P | 1 |
| Emmerich, J | 1 |
| Fauret, AL | 1 |
| Fiessinger, JN | 2 |
| Germain, DP | 1 |
| Georgesco, G | 1 |
| Hulot, JS | 1 |
| De Paepe, A | 1 |
| Plauchu, H | 1 |
| Laurent, S | 1 |
| Lum, YW | 1 |
| Black, JH | 1 |
| Jamard, A | 1 |
| Le Hello, C | 1 |
| Simonet, T | 1 |
| Dreyfus, M | 1 |
| Lahlou-Laforêt, K | 1 |
| Khau Van Kien, P | 1 |
| Sapoval, M | 1 |
| Julia, P | 1 |
| Zinzindohoué, F | 1 |
| Touraine, P | 1 |
| Dumez, Y | 1 |
| Trystram, D | 1 |
| Vignal-Clermont, C | 1 |
| Gimenez-Roqueplo, AP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prevention of Vascular Complications by BetaBlocker Treatment in Vascular Ehlers-Danlos Syndrome[NCT00190411] | Phase 4 | 54 participants (Actual) | Interventional | 2003-10-31 | Completed | ||
| Angiotensin II Receptor Blockade in Vascular Ehlers Danlos Syndrome: a Double Blind, Randomized, Placebo Controlled, Multicenter Trial.[NCT02597361] | Phase 3 | 61 participants (Actual) | Interventional | 2016-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for celiprolol and Cutis Elastica
| Article | Year |
|---|---|
Topics: Adrenergic beta-Antagonists; Celiprolol; Clinical Trials as Topic; Drug Repositioning; Ehlers-Danlos | 2020 |
Contemporary management of vascular Ehlers-Danlos syndrome.
Topics: Antihypertensive Agents; Celiprolol; Collagen Type III; Ehlers-Danlos Syndrome; Embolization, Therap | 2011 |
[Vascular Ehlers-Danlos syndrome].
Topics: Adult; Ascorbic Acid; Celiprolol; Child; Clinical Trials as Topic; Collagen Type III; Contraception; | 2006 |
1 trial available for celiprolol and Cutis Elastica
| Article | Year |
|---|---|
Effect of celiprolol on prevention of cardiovascular events in vascular Ehlers-Danlos syndrome: a prospective randomised, open, blinded-endpoints trial.
Topics: Adolescent; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Adult; Aneurysm, Ruptured; Aortic | 2010 |
Effect of celiprolol on prevention of cardiovascular events in vascular Ehlers-Danlos syndrome: a prospective randomised, open, blinded-endpoints trial.
Topics: Adolescent; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Adult; Aneurysm, Ruptured; Aortic | 2010 |
Effect of celiprolol on prevention of cardiovascular events in vascular Ehlers-Danlos syndrome: a prospective randomised, open, blinded-endpoints trial.
Topics: Adolescent; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Adult; Aneurysm, Ruptured; Aortic | 2010 |
Effect of celiprolol on prevention of cardiovascular events in vascular Ehlers-Danlos syndrome: a prospective randomised, open, blinded-endpoints trial.
Topics: Adolescent; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Adult; Aneurysm, Ruptured; Aortic | 2010 |
7 other studies available for celiprolol and Cutis Elastica
| Article | Year |
|---|---|
Vascular Ehlers-Danlos syndrome: can the beneficial effect of celiprolol be extrapolated to bisoprolol?
Topics: Adrenergic beta-1 Receptor Antagonists; Animals; Aorta, Thoracic; Aortic Aneurysm, Thoracic; Aortic | 2020 |
Medical Therapy Affects the Arteriopathy of Vascular Ehlers-Danlos Syndrome.
Topics: Celiprolol; Ehlers-Danlos Syndrome; Humans; Vascular Diseases | 2021 |
Celiprolol Treatment in Patients with Vascular Ehlers-Danlos Syndrome.
Topics: Adolescent; Adrenergic beta-1 Receptor Antagonists; Adult; Aged; Celiprolol; Dose-Response Relations | 2021 |
Vascular Ehlers-Danlos Syndrome: Long-Term Observational Study.
Topics: Adult; Celiprolol; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; E | 2019 |
Celiprolol but not losartan improves the biomechanical integrity of the aorta in a mouse model of vascular Ehlers-Danlos syndrome.
Topics: Adrenergic beta-1 Receptor Antagonists; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta, Tho | 2020 |
Celiprolol therapy for vascular Ehlers-Danlos syndrome.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Aneurysm, Ruptured; Aortic Dissection; Celipr | 2010 |
[Vascular Ehlers-Danlos syndrome and pregnancy: an obstetrical specific support].
Topics: Adult; Celiprolol; Ehlers-Danlos Syndrome; Female; Humans; Infant, Newborn; Male; Pregnancy; Pregnan | 2012 |